Risk Factors Update Summary

• The reporting date changed from December 2019 to December 2018, impacting historical financial data.
• The estimated cash runway extended from late July 2024 to December 2023.
• The change from "we will" to "we may" regarding the ability to raise additional funding is significant.
• Added "current or future" to products subject to patent limitations. This change expands potential risks.
• Net losses decreased significantly from approximately $52 million to $12 million.
• The number of product candidates mentioned decreased from 52 to 41.
• Added administrative proceedings to litigation risks. This change might result in increased legal costs.
• Changed "pharmaceutical" to "biotechnology" in stock volatility risks. This change reflects industry-specific challenges.
• Cash and cash equivalents decreased from $52 million to $12 million.
• The potential need for additional capital was highlighted due to uncertainties about continuing as a going concern.
• Increased the number of patent applications from 59 to 73. This change indicates a focus on intellectual property protection.
• Increased the number of intellectual property rights from 60 to 79. This change highlights the importance of IP protection.
• Changed "substantial" to "large" in describing discovery requirements. This change may impact legal expenses.
• Increased ownership stake from 16% to 17.7%. This change may affect corporate governance decisions.